期刊文献+

维持性血液透析患者血清钙、磷及甲状旁腺激素水平的横断面调查 被引量:10

Cross-sectional survey on serum calcium,phosphorus and PTH level in maintained hemodialysis patients
下载PDF
导出
摘要 目的调查我院维持性血液透析(血透)患者中钙磷代谢紊乱及继发性甲状旁腺功能亢进症的发生情况。方法以182例血透患者作为调查对象,所有患者透析龄>3个月。采用放射免疫法检测患者透前全段甲状旁腺激素(iPTH)水平。对iPTH与血钙、血磷、血清白蛋白浓度、透析龄及透析频率等指标的相关性进行多元逐步回归分析。结果 182例调查对象血清钙浓度达标91例(50.0%),血磷浓度达标49例(26.9%),钙磷乘积达标70例(38.5%),iPTH浓度达标41例(22.5%),仅有29例(15.9%)的患者所有指标均达到控制目标值。多元逐步回归分析显示,iPTH与残余尿量和透析龄相关。结论维持性血透患者钙磷代谢紊乱及继发性甲状旁腺功能亢进治疗达标率仍较低。 Objective To investigate the condition of calcium and phosphorus disturbance and secondary hyperparathyroidism in maintained hemodialysis(HD) patients with chronic kidney disease(CKD).Methods 182 maintained HD patients were selected.The dialysis period of all patients were longer than 3 months.The fasting serum iPTH levels of patients were measured by radioimmunoassay.The relationships between iPTH and serum calcium,serum phosphorus,serum albumin,dialysis frequency,and dialysis age were analyzed by multivariable logistic regression analysis.Results The levels of serum calcium and phosphorus fell within the range recommended 50% and 26.9% respectively.PTH levels were within the recommended values in 22.5% of the determinations.38.5% of the determinations for the calcium-phosphorus product was 55 mg2/dl2.Only 15.9% of the determinations met all four criteria.Multivariable regression analysis showed that there were correlation between iPTH and dialysis age,residual urine volume.Conclusion Calcium-phosphorus disturbance and secondary hyperparathyroidism in maintenance hemodialysis patients didn't be controlled well.
出处 《海南医学》 CAS 2011年第10期144-146,共3页 Hainan Medical Journal
基金 深圳市科技计划项目(201003072)
关键词 维持性血液透析 甲状旁腺激素 钙代谢障碍 磷代谢障碍 残余尿量 Maintenance hemodialysis Parathyroid hormone Calcium metabolism disorder Phosphorus metabolism disorder Residual urine volume
  • 相关文献

参考文献11

  • 1National Kideny Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease [J].Am J Kidney Dis, 2003, 42(4 Suppl 3): 1-201.
  • 2Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease [J]. Am J Kidney DIS, 2003, 42(2): 197-201.
  • 3Kim J, Danese S, Satayathum P, et al. Achievement of proposed NKF-K/DOQI bone metabolism and disease guidelines: results from the dialysis outcomes and practice patterns study (DOPPS) [J]. J Am Soc NephroI, 2003, 14(11): 269-270.
  • 4Block GA, Port FK. Re-evaluation of risks associated with hyper- phosphatemia and hyperparathyroidism in dialysis patients. Rec- ommendations for a change in management [J]. Am J Kidney DIS, 2000, 35(6): 1226-1237.
  • 5Cannata-Andia J, Diaz-Corte C. Applying the K/DOQI guidelinescut-of levels to the dialysis population: How far are we from the target? [J]. JAm So Nephrol, 2003(14): 474.
  • 6Noordzi .IM, Korevaar JC, Boeschoten EW, et al. The kidney disease outcomes ouality Initiative (K/DOQI) guideline for bone metabolism and disase in CKD: association with mortality in dialysis patients [J]. Am J Kidney Dis, 2005, 46(5): 925-932.
  • 7孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 8Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB. Bone metabolism,vascular calcifications and rnortality: associations beyond mere coincidence [J]. J Nephrol, 2005, 18(4): 458-463.
  • 9Ketterler M, GrossML, Ritz E. Calcification and cardiovascular problems in renal failure [J].Kideny Int SuppI, 2005(94): 120-127.
  • 10Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO44 Ca × PO, product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients [J]. J Am Soc Nephrol, 2001, 12(10): 2131-2138.

二级参考文献18

  • 1Lemann JJ, Litzow JR, Lennon EJ. The effect of chronic acid loads in normal man: Further evidence against chronic metabolic acidosis[J]. J Clin Invest, 1966, 45:1608-1614
  • 2Lemann JJ, Litzow JR, Lennon EJ. Studies of the mechanism by which chronic metabolic acidosis augment urinary calcium excretion in man[J]. J Clin Invest, 1967, 46:1318-1328
  • 3Craig BL. Calcitriol metabolism during chronic metabolic acidosis[J]. Semin Nephrol, 1989, 9:65-71
  • 4Kurz P, Monier Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease[J]. Kidney Int, 1994, 46:855-861
  • 5Nakano Y, Oshima T, Sasaki S, et al. Vitamin D receptor gene polymorphism is associated with serum total and ionized calcium concentration[J]. J Mol Med, 2000, 78:575-579
  • 6Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calciumХphosphorus product with mortality risk in chronic hemodialysis patients: a national study[J]. Am J Kidney Dis, 1998, 31: 607-617
  • 7Amann K, Gross ML, London GM, et al. Hyperphosphataemia-a silent killer of patients with renal failure[J]? Nephrol Dial Transplant, 1999, 14:2085-2087
  • 8Brenner BM. The Kidney[M]. 北京: 科学出版社,2001. 520-556
  • 9Goldfarb S. Renal osteodystrophy, disorders of divalent ion metabolism, and nephrolithiasis[J]. Nephrology Self-Assessment Program, 2002, 1: 55-68
  • 10Cannata-Andia JB. Pathogenesis, prevention and management of low-bone turnover[J]. Nephrol Dial Transplant, 2000, 15(Suppl 5): 15-17

共引文献62

同被引文献96

引证文献10

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部